Dystrophin replacement strategies are hopeful for addressing upstream dystrophin deficiency; however, all methods to date use semi-functional dystrophin proteins that are likely to trigger downstream pathways. This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.